ArticleCardiovascular diabetology2026
GULP1 protects against diabetic cardiomyopathy through IKIP/NF-κB-dependent improvement of mitochondrial function.
Article in Cardiovascular diabetology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recent advances in mitochondrial fission and fusion in diabetic cardiomyopathy.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundMitochondrial structural abnormalities and impaired energy metabolism are recognized hallmarks of diabetic cardiomyopathy (DCM). GULP1 (PTB-domain engulfment adapter protein 1, also known as CED-6) is a cytoplasmic adaptor protein containing a phosphotyrosine-binding domain. GULP1 has been implicated in metabolic disorders, particularly in type 2 diabetes. However, its potential involvement in cardiovascular homeostasis remains unclear. This study aimed to investigate whether GULP1 attenuates DCM by preserving mitochondrial architecture and bioenergetic function, and to explore the underlying molecular mechanisms.
methodsCardiac-specific Gulp1 knockout (Gulp1KO) and overexpressing (Gulp1KI) mice, along with their wild-type littermates (Gulp1f/f, Gulp1WT), were fed a high-fat diet for 6 months to induce DCM. Cardiac function was assessed by echocardiography and hemodynamic measurements. Cardiac mitochondrial structure and function were evaluated using electron microscopy, enzyme activity assays, ATP production and fatty acid oxidation. Primary ventricular myocytes derived from neonatal and adult mice were employed to delineate the molecular and signaling mechanisms underlying GULP1-mediated protection against palmitic acid (PA)-induced mitochondrial morphological alterations and dysfunction.
resultsGULP1 expression was markedly reduced in myocardial tissues from DCM patients and mouse models. Cardiac-specific GULP1 overexpression significantly attenuated cardiac dysfunction, alleviated mitochondrial structural disruption and respiratory impairment in diabetes, while reducing oxidative stress and cardiomyocyte apoptosis. Mechanistically, GULP1 directly interacted with IKIP (inhibitor of nuclear factor κB kinase-interacting protein) to alleviate IKIP-mediated inhibition of IKKβ-dependent NF-κB activation. This interaction enhanced NF-κB signaling, upregulated OPA1 (optic atrophy 1) expression and restored mitochondrial morphology, while improving fatty acid metabolism in DCM hearts. Consistently, GULP1 prevented PA-induced mitochondrial dysfunction, oxidative stress, and cardiomyocyte apoptosis in vitro through the IKIP/NF-κB/OPA1 signaling axis.
conclusionsThe IKIP/NF-κB/OPA1 signaling axis constitutes an essential mechanism through which GULP1 preserves mitochondrial morphofunction, thereby translating into cardioprotection against diabetic cardiomyopathy. These results identify GULP1 as a compelling therapeutic target for DCM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.